AI Insight
Researchers developed a new mathematical model for predicting how bispecific antibodies, which link immune cells to cancer cells, behave at the immunological synapse level. Unlike existing models that treat tumor environments as uniformly mixed, this synapse-based model accounts for individual cell-to-cell interactions and demonstrates that the number of trimers (CD3:antibody:tumor antigen complexes) per synapse remains constant regardless of the ratio of immune cells to tumor cells at a given antibody concentration. The model was validated against existing approaches and successfully integrated into tumor growth inhibition simulations, offering more precise predictions for drug development.
Why it matters
This modeling approach could improve the design and dosing predictions for bispecific antibody therapies in early clinical trials, potentially accelerating development of cancer treatments like elranatamab for multiple myeloma. More accurate preclinical predictions may reduce the time and cost of bringing these immunotherapies to patients.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Immune cell engagers (ICE) such as bispecific antibodies (bsAbs), within an immunological synapse, bind and link CD3 on a T cell to a target antigen (TAA) on a cancer cell, forming a trimer (CD3:bsAb:TAA complex). With sufficient trimer numbers within the synapse, the T cell can become activated and promote cancer cell killing. Elranatamab, a CD3-bispecific antibody for multiple myeloma, has received FDA and EMA filing acceptance (August 2023 and December 2023, respectively) adding to a growing list of bsAbs that are treating patients. In the drug development stages of ICE bsAbs, mechanistic modeling approaches are often used to attain a greater quantitative understanding of the modality, preclinically, and provide human pharmacokinetic and efficacious dose predictions to aide in Phase 1 trial design. To date, the majority of ordinary differential equation (ODE) trimer models treat the tumor compartment as well-mixed and trimer formation is governed by a bulk population reaction not accounting for individual synapses. This lack of discrimination can lead to imprecise analysis when analyzing results across E:T ratios using metrics like trimers per T cell or trimers per target cell. To this end we developed an ODE trimer model based on single-synapse complexes (one target cell/one immune cell) with 2D cross-linking trimer formation. We show computationally that the number of trimers per synapse is invariant to the value of the E:T ratio for a given free bsAb concentration, a property that cannot be captured by non-synapse models. A simple demonstration of this discrepancy using the well-known Betts trimer model is presented. We then apply the Betts trimer model coupled to a tumor growth inhibition (TGI) module to show that our synapse-based trimer model is easy to substitute in to model TGI, including the addition of a trimer-per-synapse activation threshold function for cell killing. Overall, our model attempts to balance mechanistic fidelity while limiting the complexity of the model.